A compelling body of evidence links pesticide exposure to human diseases. The liver plays a central role in the detoxification of pesticides, suggesting intense pesticide–liver cell interactions. A growing body of studies highlighted in this review supports the contribution of pesticides of various chemical classes to the development of non-alcoholic fatty liver disease (NAFLD), alcohol-associated liver disease (ALD), liver cirrhosis, viral hepatitis, hepatocellular carcinoma, etc., via disrupting lipid and carbohydrate metabolism and redox homeostasis, promoting endoplasmic reticulum stress and mitochondrial dysfunction, as well as stimulating apoptosis, fibrosis, and inflammation. In this review, we systematically illustrated an underappreciated mechanism of pesticide-induced overall and hepatic toxicity, i.e., the ability to induce non-apoptotic regulated cell death (RCD) pathways such as ferroptosis, necroptosis, and pyroptosis. Our analysis indicates that pesticides are implicated in driving liver diseases by inducing ferroptosis, necroptosis, and pyroptosis. Non-apoptotic RCDs mediate pesticide-induced liver steatosis and fibrosis. Furthermore, these cell death modalities fuel inflammation through the promotion of pro-inflammatory cytokine production and the generation of damage-associated molecular patterns. Understanding of deeper mechanisms of pesticide-induced effects on the non-apoptotic cell death machinery and subsequent immunogenic effects in liver pathology might help develop novel preventive strategies to reduce liver damage.

A BSTRACT: Background: The increasing use of diagnostic imaging procedures involving ionizing radiation, particularly computed tomography (CT), has improved diagnostic capabilities while raising concerns regarding patient and occupational radiation exposure. Consequently, radiation safety has become an important component of healthcare quality management and patient safety. Modern radiation protection systems require integrated organizational and quality management approaches beyond technical compliance alone. The study aimed to analyze current approaches to the organization of radiation safety in medical institutions and evaluate assessment criteria and quality management strategies. Materials and Methods: A narrative expert review was conducted using publications identified through PubMed, Scopus, Web of Science, and Google Scholar, with the final search performed on June 25, 2026. The evidence was synthesized descriptively across the principal organizational, regulatory, technical, and quality-management domains of radiation safety. Scientific articles, international guidelines, regulatory documents, and quality management recommendations published mainly between 2000 and 2026 were analyzed. The review focused on organizational, regulatory, technical, and quality management aspects of radiation safety in healthcare institutions. Results: Effective radiation safety systems require integrated organizational frameworks including qualified personnel, radiation safety committees, quality assurance programs, clinical audits, dose monitoring systems, and continuous staff training. The Structure–Process–Outcome model was identified as a practical framework for assessing radiation safety effectiveness using structural, process, and outcome indicators. Major organizational challenges include insufficient training, outdated equipment, weak safety culture, and variability between institutions. Modern quality management approaches, including corrective and preventive actions systems, risk-based management, digital audits, and automated dose monitoring technologies, contribute to the optimization of radiation protection practices and continuous quality improvement. Conclusion: Integrated management approaches combining quality assurance, continuous monitoring, and organizational support are essential for effective and sustainable radiation safety in modern diagnostic radiology.

A BSTRACT: Hereditary angioedema (HAE) is a bradykinin-driven disorder marked by unpredictable, potentially life-threatening edema and evolving therapeutic complexity. Here, we provide an updated, evidence-integrated synthesis of contemporary HAE diagnosis and management (2010 present), combining guideline recommendations, randomized trials, and regulatory data into a unified clinical framework. Diagnosis is reframed as an algorithmic process that integrates clinical phenotyping with complement testing, while highlighting the expanding genetic landscape and diagnostic uncertainty of HAE with normal C1 inhibitor (HAE-nC1INH). Therapeutic paradigms have shifted toward mechanism-based precision interventions, including plasma kallikrein inhibition, factor XIIa blockade, and RNA-targeted therapies, alongside emerging oral on-demand options that enable early, patient-directed treatment. The novelty of this review lies in its integration of rapidly evolving therapeutic classes with practical, guideline-aligned diagnostic and treatment algorithms, while explicitly addressing real-world implementation challenges, including access, monitoring, and patient-centered decision-making. Despite major advances, key gaps remain in biomarker validation, comparative effectiveness, and global accessibility. This work positions HAE as a model for precision medicine in rare diseases and provides a clinically actionable roadmap for translating innovation into practice.

A BSTRACT: Background: Targeted immunobiological therapies have transformed the management of severe asthma by enabling precision medicine approaches. However, the rapidly expanding body of literature necessitates systematic evaluation to identify research trends and emerging directions. Objective: This study aimed to perform a comprehensive bibliometric analysis of global research on targeted immunobiological therapy in severe asthma. Materials and Methods: A total of 768 articles published between 2021 and 2026 were retrieved from the Web of Science Core Collection. Bibliometric analysis was conducted using Biblioshiny (Bibliometrix R package), and data visualization was performed using Python-based tools. Key indicators, including publication trends, leading authors, institutions, countries, journal impact, collaboration networks, and keyword co-occurrence, were analyzed. Results: The results demonstrated a steady increase in annual publications, with peak productivity in 2025. The United States, Italy, and the United Kingdom were the leading contributors, supported by strong international collaborations. Prominent institutions and authors played central roles in advancing the field. Keyword analysis revealed a dominant focus on biologic therapies such as mepolizumab, omalizumab, and benralizumab, alongside core themes of efficacy, inflammation, and eosinophilic pathways. Thematic mapping identified well-established motor themes and emerging areas related to biomarkers and personalized medicine. Conclusion: The field of targeted immunobiological therapy in severe asthma is rapidly expanding, with a strong emphasis on precision medicine. This study provides valuable insights into research trends and future directions, supporting the continued development and optimization of biologic therapies.